Review anchor
Cyclic nucleotide-gated channel alpha-1
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
Evidence Snapshot
Cyclic nucleotide-gated channel alpha-1
CHEMBL4907
SINGLE PROTEIN
Bos taurus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cyclic nucleotide-gated channel alpha-1 as ChEMBL target CHEMBL4907, mapped to UniProt Q00194. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4907
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00194
Cyclic nucleotide-gated channel alpha-1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Cyclic nucleotide-gated channel alpha-1 matters
Cyclic nucleotide-gated channel alpha-1 is reviewed as Cyclic nucleotide-gated channel alpha-1 (UniProt Q00194); the current evidence base includes 1 approved drug, 7 compounds, and 2 assays, with lead potency reaching pChEMBL 10.5.
Protein context
Cyclic nucleotide-gated channel alpha-1
Cyclic nucleotide-gated channel alpha-1 Sequence length is 690 aa.
Review this target as Cyclic nucleotide-gated channel alpha-1, mapped to UniProt Q00194. Sequence length is 690 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q00194
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 7 compounds, and 2 assays for this target. The dominant activity type is KD. CHEMBL1917652 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL1917652 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Cyclic nucleotide-gated channel alpha-1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q00194, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
7
Total Compounds
2
Total Assays
1
Approved Drugs
KD: 14.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1917652
|
10.5 | Kd | — |
|
|
No preferred name
CHEMBL3559600
|
7.1 | Kd | — |
|
|
No preferred name
CHEMBL195005
|
5.5 | Kd | — |
|
|
No preferred name
CHEMBL698
|
5.2 | Kd | Approved |
Source Header